Topical Calcineurin Inhibitors: Tacrolimus and Pimecrolimus

Mechanism

Pharmacological Class and Group

Topical non-steroidal macrolide immunomodulators, belonging to the group of Calcineurin Inhibitors.

Mechanism of Action

Tacrolimus and pimecrolimus selectively penetrate the plasma membrane of the T helper lymphocytes (Th1 and Th2) of the inflamed dermis.

Calcineurin and NFAT Blocking Mechanism

1. Binding to Immunofilin FKBP-12: The drugs selectively bind to the cytosolic intracellular macrophage immunophilin receptor protein FKBP-12 (FK-binding protein 12), forming an active molecular complex.

2. Calcineurin Phosphatase Inhibition: The Tacrolimus-FKBP-12 complex couples to the calcium and calmodulin-dependent cytoplasmic phosphatase: calcineurin. This competitively blocks the enzymatic activity of the phosphatase.

3. Blocking of NFAT Dephosphorylation: As calcineurin is inhibited, the essential dephosphorylation of the nuclear transcription factor of activated T lymphocytes (NFAT) is prevented:

Inhibition of Calcineurin Blockade of NFAT Translocation Lack of IL-2 Synthesis

4. Suppression of proinflammatory Cytokines: Without the nuclear translocation of NFAT, the transcription and release of Interleukin-2 (IL-2) and other cytokines (IL-3, IL-4, IL-10, TNF-α, IFN-γ) are abolished, stopping the activation and clonal expansion of pathological cutaneous T lymphocytes.

Pharmacokinetics

High Resolution Pharmacokinetics

• Systemic Absorption: Extremely low. In patients with intact skin, the systemic bioavailability of topical tacrolimus is less than 0.5%. In severe atopic dermatitis with massive barrier dysfunction, absorption may increase slightly at the beginning of treatment, decreasing progressively as the skin re-epithelializes and integrates.
• Metabolism: The tiny fraction absorbed systemically is extensively metabolized in the liver by the cytochrome CYP3A4 system. It has no measurable systemic tissue accumulation.

Indicators and dose

Clinical Indications and Off-Label Uses

• Moderate to Severe Atopic Dermatitis: Of choice both for the management of acute outbreaks and for long-term maintenance therapy, especially in sensitive areas (face, neck, eyelids and skin folds) where corticosteroids are restricted due to the risk of atrophy.
• Focal Vitiligo (off-label): Stimulates repigmentation by attenuating the destruction of melanocytes mediated by cytotoxic T lymphocytes, usually combined with phototherapy.
• Rosacea and Perioral Dermatitis (off-label): Therapeutic alternative to reduce erythema and inflammation without risk of acneiform rebound.
• Inverse and Intertriginous Psoriasis (off-label): Highly effective in flexural folds.

Dosage and Clinical Adjustment

• Tacrolimus Ointment 0.1% (Adults): Apply in a thin layer on active eczema plaques twice a day until the condition resolves.
• Tacrolimus Ointment 0.03% (Pediatric from 2 to 15 years): Apply twice a day.
• Pimecrolimus Cream 1%: Preferably indicated for mild-moderate facial eczema. Apply twice a day.
• Proactive Maintenance Therapy: Once clinical remission of eczema is achieved, apply tacrolimus two nights per week (e.g., Wednesdays and Sundays) indefinitely to maintain cutaneous immune homeostasis.

Security

Absolute and Relative Contraindications

Absolute Contraindications

• Known hypersensitivity to rapamycin class macrolides or tacrolimus.
• Bacterial, herpetic or viral infections in the area to be treated.
• Netherton syndrome or other severe congenital disorders of the skin barrier that substantially increase systemic absorption in an uncontrolled manner.

Relative Contraindications

• Active systemically immunosuppressed patients.
• Skin lesions suspicious of malignancy or premalignant lesions in the application area.

Adverse Effects (ADR) and Specific Toxicity

• Very common (>30%): Sensation of burning, burning and immediate local itching at the application site. It tends to self-limit after the first 3 to 5 days of continuous use, as the dermoepidermal inflammation subsides.
• Frequent (1%-10%): Superficial folliculitis, local intolerance to alcohol (feeling of suffocation and intense facial heat after ingesting alcoholic beverages), local reactivation of herpes simplex virus infections (eczema herpeticum).
• Rare: Cutaneous lymphomas or squamous cell carcinoma (FDA Black Box Warning based on theoretical data and preclinical models; long-term follow-up human cohort epidemiologic studies have not confirmed this causal association at standard therapeutic doses).

Drug Interactions of Clinical Relevance

Due to the negligible systemic absorption in daily clinical practice, there are no relevant drug interactions mediated by CYP3A4, except in patients with large eroded body surfaces treated with occlusive dressings.

Safety in Pregnancy and Breastfeeding

• Pregnancy: Not recommended. Although absorption is minimal and topical preclinical studies do not show teratogenicity, it is advisable to restrict its use due to the lack of prospective controlled studies in pregnant women, favoring the temporary use of hydrocortisone.
• Breastfeeding: Compatible. It is excreted in breast milk in clinically null quantities. It must be ensured that the infant does not come into direct physical contact with the treated skin area on the maternal breast.

Clinical

Clinical Pearl: Mitigation of Burning by Tacrolimus

To significantly reduce the initial burning that usually causes the patient to abandon treatment prematurely, it is recommended to apply tacrolimus only to completely dry skin (wait 20-30 minutes after bathing). Additionally, you can store the tube in the refrigerator (cold application decreases the local release of substance P from cutaneous nociceptors) or pretreat the highly inflamed lesion with a class II topical corticosteroid during the first 3 days.